Treatment for glioblastoma (GBM)
Intended for US audiences only.
Optune® Novocure™

Recurrent GBM safety

Optune patients experienced fewer systemic adverse events vs chemotherapy1

Incidence of grade 3/4 AEs occurring in ≥2% of patients2

System Organ Class Adverse Event Optune
(n=116)
Chemotherapy*
(n=91)
Blood and Lymphatic
System Disorders
Thrombocytopenia 0% 2%
Gastrointestinal Disorders Diarrhea 0% 2%
Neoplasms Benign, Malignant,
and Unspecified
Neoplasm
Progression
2% 1%
Nervous System Disorder Headache 2% 0%
Convulsion 3% 2%
Vascular Disorders Pulmonary
Embolism
1% 2%
*Therapy options were the physician's best choice for chemotherapy, including bevacizumab, which were defined given historical assessment of effective recurrent GBM therapies. The best available therapy was prescribed according to local practice and depending on prior treatment exposure.

  • The most common (≥10%) adverse events seen with Optune monotherapy were medical device site reaction and headache2

  • The following adverse reactions were considered related to Optune: medical device site reaction, headache, malaise, muscle twitching, fall, and skin ulcer3

    • In EF-11, 16% of patients experienced a grade 1/2 medical device site reaction2,3

  • Mild to moderate skin irritation, the most common device-related side effect with Optune, was easily manageable, reversible, and did not result in treatment discontinuation1

Patient educational materials

Download and print information to introduce Optune to your patients.

View the results

Quick facts about Optune

Find out more about Optune and how to start patients on therapy.

View now

Improved safety vs chemotherapy1



AE, adverse event; GBM, glioblastoma.

References: 1. Optune Instructions For Use. Novocure 2016. 2. Novocure Data on File. OPT-109. 3. Novocure Data on File. OPT-100.

Patient educational materials

Download and print information to introduce Optune to your patients.

View the results

Quick facts about Optune

Find out more about Optune and how to start patients on therapy.

View now

OPT-055.3-04


Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information

Contraindications

Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

The most common (≥10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.

The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.


Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Patient Journey videos on this site depict actual patients and caregivers. All other depictions of patients, caregivers and health care professionals are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).